WATERTOWN, Mass.--(BUSINESS WIRE)--
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2017, after the U.S. markets close on August 7, 2017. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline.
Conference Call and Webcast Information
To participate in
the live conference call, please dial (855) 840-0595 in the U.S. or
(518) 444-4814 for international callers. A replay of the conference
call will be available starting at approximately 7:30 p.m. ET on August
7, 2017, through 11:59 p.m. ET on August 10, 2017 by dialing (855)
859-2056 from the U.S. or (404) 537-3406 for international callers. The
passcode for both the live call and the replay is 47670579. A live audio
webcast of the call and replay can be accessed by visiting the “Events
and Presentation” section on the “Investors” page of Enanta’s website at www.enanta.com.
About Enanta
Enanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases. Enanta’s
research and development efforts are currently focused on the following
disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary
cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B
virus (HBV). Enanta has also discovered novel protease inhibitors that
have been developed as part of AbbVie’s hepatitis C virus (HCV)
treatment regimens under a collaboration that now provides Enanta a
payment stream, which it is using to fund its research and development
programs. Please visit www.enanta.com
for more information on Enanta’s programs and pipeline.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170725005229/en/
